Title   A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Nation     Phase   Phase 2     Date Added   2023-05-30     Location   Brazil     China   Georgia     Greece   Hungary     New Zealand   Romania     South Artica   Turkey     Prior IO Allowed   No     Status   Active, not recruiting     Drugs   INCB09280     Title   A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia     Phase   Phase     Date Added   2023-05-19     Location   California, United States     New York, United States   New York, United States     Oregoin, United States   New York, United States     New York, United States   New York, United States     Oregoin, United States   New York, United States     Oregoin, United States   New York, United States     Oregoin, United States   New York, U		
Phase     Phase 2       Date Added     2023-05-30       Location     Brail China Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia South Artica Tutkey     South Artica Tutkey       Prior IO Allowed     No       Status     Active, not recruiting       Prior IO Allowed     No TOS966535       Title     A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia       Phase     Phase 1       Date Added     2023-05-19       Location     Callornia, United States Tennessee, United States New York, United States		NCT05879822
Date Added   2023-05-30     Location   Brazil China Georgia Georgia Greece Hungay New Zealand Romania South Arica Tutkey     Prior IO Allowed   No     CRC-directed   No     Status   Active, not recruiting     Drugs   INCB69260     Tags   NoT0586535     Title   No 203-05-19     Date Added   2023-05-19     Date Added   2023-05-19     Location   Calloma, United States Georgia, United States Fronda, United States Georgia, United States Fronda, United States Fronda, United States Georgia, United States Fronda, United States Corgon, United States Corgon, United States Fronda, United States Fronda, United States Fronda, United States Corgon, United States Fronda, Unite		
LocationBrazil China Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Georgia Consolitation TurkeyPrior IO AllowedNoORC-directedNoORC-directedNoData Active, not recruitingNoDrugsNSI-H/ MMRdNCT IDNCT0586535TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Data AddedCalifornia, United States Florida, United States Coregon, United States South Carolina, United States New York, United States South Carolina, United States New York, United States Neurolas, United States <br< th=""><th>Phase</th><th>Phase 2</th></br<>	Phase	Phase 2
China Georgia Greece Hugay New Zealand Romania South Africa TurkeyPrior IO AllowedNoCRC-directedNoStatusActive, not recruitingDrugsINCB86533TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Date Added2023-05-19LocationCalifornia, United States Florida, United States Oregon, United States Oregon, United States Oregon, United States Oregon, United States Texas, United States Oregon, Unit	Date Added	2023-05-30
CRC-directedNoStatusActive, not recruitingDrugsINCB099280TagsMSI-H/ MMRdNCT DNCT0586535TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Data Added2023-05-19LocationCalifornia, United States Florida, United States Oregon, United States Tenesees_United States Tenese_United States Tenese_Unit	Location	China Georgia Greece Hungary New Zealand Romania South Africa
StatusActive, not recruitingDrugsINCB099280TagsMSI-H/ MMRdNCT IDNCT05865335TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Date Added2023-05-19LocationCalifornia, United States Forda, United States Georgia, United States New York, United States Oregon, United States Texas, United States 	Prior IO Allowed	No
DrugsINCB099280TagsMSI-H/ MMRdNCT IDNCT05886535TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Date Added2023-05-19LocationCalifornia, United States Florida, United States Nebraska, United States Nebraska, United States 	CRC-directed	No
TagsMSI-H/ MMRdNCT IDNCT05865535TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Date Added2023-05-19LocationCalifornia, United States Georgia, United States Nebraska, United States Oregon, United States Nebraska, United States Tennessee, United States South Carolina, United States Tennessee, United States Tennessee, United States South Carolina, United States South Carolina, United States Tennessee, United States South Carolina, United States South Caroli	Status	Active, not recruiting
NCT ID   NCT05865535     Title   A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia     Phase   Phase 1     Date Added   2023-05-19     Location   California, United States Florida, United States Georgia, United States New York, United States New York, United States New York, United States     Prior ID Allowed   No     CRC-directed   No     Status   Recruiting     Drugs   Tags     MSI-H/ MMRd, MSS/ MMRp     NCT ID   NCT05838768     Title   Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Insta or Mismatch Repair Deficiency.	Drugs	INCB099280
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With CachexiaPhasePhase 1Date Added2023-05-19LocationCalifornia, United States Fiorida, United States Nebraska, United States Oregon, United States Nebraska, United States Oregon, United States Tennessee, United States Tennessee, United States Texas, United States 	Tags	MSI-H/ MMRd
PhasePhase 1Date Added2023-05-19LocationCalifornia, United States Florida, United States Georgia, United States Nebraska, United States Nebraska, United States Nebraska, United States Tennessee, United States Tennessee, United States Texas, United States T	NCT ID	NCT05865535
Date Added2023-05-19LocationCalifornia, United States Florida, United States Georgia, United States Nebraska, United States Oregon, United States Texas, United States Tex	Title	A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
LocationCalifornia, United States Florida, United States Georgia, United States Nebraska, United States New York, United States New York, United States Tennessee, United	Phase	Phase 1
Florida, United States Georgia, United States Nebraska, United States Nebraska, United States New York, United States Oregon, United States Tennessee, United States Tennessee, United States Texas, U	Date Added	2023-05-19
CRC-directedNoStatusRecruitingDrugsMSI-H/ MMRd, MSS/ MMRpNCT IDNCT05838768TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Insta or Mismatch Repair Deficiency.	Location	Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States
Status Recruiting   Drugs MSI-H/ MMRd, MSS/ MMRp   Tags MSI-H/ MMRd, MSS/ MMRp   NCT ID NCT05838768   Title Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instation or Mismatch Repair Deficiency.	Prior IO Allowed	No
Drugs   MSI-H/ MMRd, MSS/ MMRp     NCT ID   NCT05838768     Title   Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instation or Mismatch Repair Deficiency.	CRC-directed	No
Tags   MSI-H/ MMRd, MSS/ MMRp     NCT ID   NCT05838768     Title   Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Insta or Mismatch Repair Deficiency.	Status	Recruiting
NCT ID   NCT05838768     Title   Study of HR0761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instation or Mismatch Repair Deficiency.	Drugs	
Title     Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Insta or Mismatch Repair Deficiency.	Tags	MSI-H/ MMRd, MSS/ MMRp
or Mismatch Repair Deficiency.	NCT ID	NCT05838768
Phase Phase 1	Title	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
	Phase	Phase 1
Date Added 2023-05-03	Date Added	2023-05-03

Location	California, United States
Looution	Massachusetts, United States
	New York, United States
	Texas, United States
	Belgium China
	France
	Germany
	Israel
	Italy Japan
	Korea, Republic of
	Norway
	Singapore Spain
	Sweden
	Taiwan
	United Kingdom
Prior IO Allowed	Νο
CRC-directed	Yes
Status	Recruiting
Drugs	HRO761, Irinotecan
Tags	MSI-H/ MMRd
NCT ID	NCT05799443
Title	Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2023-04-05
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	cetuximab, Irinotecan Hydrochloride, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05798533
Title	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Phase	Phase 1
Date Added	2023-04-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine, Interleukin-2
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05785325
Title	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-03-27
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting

Drugs	RC48-ADC plus Bevacizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
Title	Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2023-03-27
Location	Texas, United States Washington, United States Korea, Republic of
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	TU2218 + Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT05783089
Title	MSLN-targeted CAR-T Cells in Solid Tumors.
Phase	Phase 1
Date Added	2023-03-24
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Not yet reording
Diago	
Tags	MSI-H/ MMRd, MSS/ MMRp
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05771181
NCT ID Title	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
NCT ID Title Phase	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2
NCT ID Title Phase Date Added	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16
NCT ID Title Phase Date Added Location	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2
NCT ID Title Phase Date Added	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16
NCT ID Title Phase Date Added Location	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China
NCT ID Title Phase Date Added Location Prior IO Allowed	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp NCT05770102 DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp NCT05770102 DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp NCT05770102 DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp NCT05770102 DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2 2023-03-15
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location	NCT05771181     Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients     Phase 2     2023-03-16     China     No     Yes     Not yet recruiting     Fruquintinib, Tislelizumab, Vitamin E     MSS/ MMRp     NCT05770102     DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers     With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch     Repair Deficiency (CMMRD) Disposition     Phase 2     2023-03-15     United Kingdom
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed	NCT05771181     Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients     Phase 2     2023-03-16     China     No     Yes     Not yet recruiting     Fruquintinib, Tislelizumab, Vitamin E     MSS/ MMRp     NCT05770102     DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers     With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch     Repair Deficiency (CMMRD) Disposition     Phase 2     2023-03-15     United Kingdom     No     No
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status	NCT05771181 Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients Phase 2 2023-03-16 China No Yes Not yet recruiting Fruquintinib, Tislelizumab, Vitamin E MSS/ MMRp NCT05770102 DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2 2023-03-15 United Kingdom No
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed	NCT05771181     Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients     Phase 2     2023-03-16     China     No     Yes     Not yet recruiting     Fruquintinib, Tislelizumab, Vitamin E     MSS/ MMRp     NCT05770102     DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers     With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch     Repair Deficiency (CMMRD) Disposition     Phase 2     2023-03-15     United Kingdom     No     No     Recruiting